A Novel EGFR-TKI Inhibitor (cAMP-H3BO3 Complex) Combined With Thermal Therapy Is a Promising Strategy to Improve Lung Cancer Treatment Outcomes

Oncotarget - United States
doi 10.18632/oncotarget.17628
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Continued EGFR -TKI With Concurrent Radiation Therapy to Improve Time to Progression in Patients With Locally Progressive Non–small Cell Lung Cancer After Front-Line EGFR -TKI Treatment

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

Oncology Letters
Cancer ResearchOncology
2015English

Differentiation Therapy: A Promising Strategy for Cancer Treatment

Chinese Journal of Cancer
2016English

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance

British Journal of Cancer
Cancer ResearchOncology
2019English

P2.13-38 Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients With Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-mutated Non-Small-Cell Lung Cancer With Brain Metastases: A Retrospective Cohort Study

Cancer Management and Research
Oncology
2019English

Nimotuzumab Combined With Chemotherapy Is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer

Medical Science Monitor
Medicine
2017English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy